How did Rockwell Medicine's revenue and expenses shift in Q4 2024?

Rockwell Automation's revenue and expenses in Q4 2024 showed a notable increase in revenue and a slight rise in costs, resulting in a solid net income. Here's a detailed analysis:

1. Revenue Growth: The company's total revenue for Q4 2024 was $1.88 billion, which represents a significant increase of 11.9% compared to the previous period. This growth in revenue indicates a strong market performance and customer demand for Rockwell Automation's products and services.
2. Cost of Goods Sold (COGS): The cost of goods sold for Q4 2024 was $1.16 billion. This figure suggests that the company has seen an increase in the cost of manufacturing and delivering its products. However, the increase in revenue outpaces the increase in COGS, which is a positive sign for the company's profitability.

3. Research and Development (R&D) Expenses: The R&D expenses for Q4 2024 were not provided, but the absence of this figure in the list of changes suggests that they may have remained stable or not significantly impacted the net income.
4. Selling, General, and Administrative (SG&A) Expenses: The SG&A expenses for Q4 2024 were $476 million. This represents an increase from the previous period, indicating that the company has invested more in selling, general, and administrative activities. This could be due to strategic initiatives to expand the business or increase market penetration.
5. Net Income: The net income for Q4 2024 was $178 million. Given the increase in revenue and the rise in SG&A expenses, the net income indicates that the company has been successful in managing its costs and generating profits from its operations.

In conclusion, Rockwell Automation's Q4 2024 financial performance reflects a company that is growing its revenue while managing its expenses effectively, leading to a healthy net income. The increase in revenue and the slight rise in costs suggest a strong operational performance and a positive outlook for the company.